Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice
The luminal HER2-negative subtype is the dominant variant of metastatic breast cancer; modern combined endocrine therapy with CDK4/6 inhibitors due to significantly change the prognosis of the disease, not only for increasing progression free survival, but also for significantly prolonging the life...
| Autor principal: | |
|---|---|
| Formato: | Artículo |
| Lenguaje: | Russian |
| Publicado: |
ABV-press
2021-09-01
|
| Colección: | Опухоли женской репродуктивной системы |
| Materias: | |
| Acceso en línea: | https://ojrs.abvpress.ru/ojrs/article/view/845 |